An open label parallel randomised Phase-II comparative study to evaluate safety, tolerability and immunogenicity of two intramuscular doses of 14-valent pneumococcal polysaccharide conjugate vaccine administered 2 months apart to 12-23 month-old healthy Indian PCV-naïve toddlers

Trial Profile

An open label parallel randomised Phase-II comparative study to evaluate safety, tolerability and immunogenicity of two intramuscular doses of 14-valent pneumococcal polysaccharide conjugate vaccine administered 2 months apart to 12-23 month-old healthy Indian PCV-naïve toddlers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Pneumococcal conjugate vaccine 14-valent - Biological E Limited (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Biological E Limited
  • Most Recent Events

    • 30 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top